Trials / Completed
CompletedNCT05393895
An Evaluation of the Safety of CSF-1 in Presbyopic Subjects
A Multi-Center, Double-Masked, Vehicle-Controlled, Evaluation of the Safety of CSF-1 in Presbyopic Subjects
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 178 (actual)
- Sponsor
- Orasis Pharmaceuticals Ltd. · Industry
- Sex
- All
- Age
- 40 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, double-masked, vehicle-controlled study. The purpose of the study is to evaluate the safety of CSF-1 compared with vehicle in presbyopic subjects. Subjects will be treated for at least 6 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CSF-1 | One drop bilaterally twice daily for at least 6 weeks |
| DRUG | Vehicle | One drop bilaterally twice daily for at least 6 weeks |
Timeline
- Start date
- 2022-04-22
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2022-05-26
- Last updated
- 2025-06-11
- Results posted
- 2025-06-11
Locations
12 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05393895. Inclusion in this directory is not an endorsement.